Biotoxtech Co., Ltd. (KOSDAQ:086040)

Market Cap	41.97B
Revenue (ttm)	44.19B
Net Income (ttm)	879.45M
Shares Out	15.72M
EPS (ttm)	-1.26
PE Ratio	47.73
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,485
Average Volume	30,388
Open	2,805.00
Previous Close	2,805.00
Day's Range	2,660.00 - 2,805.00
52-Week Range	2,585.00 - 4,250.00
Beta	0.23
RSI	42.82
Earnings Date	Mar 20, 2026

About Biotoxtech

Biotoxtech Co., Ltd. engages in the safety evaluation of synthetic medicines, biomedicines, cell therapy products, gene therapy products, health functional foods, chemicals, and pesticides in South Korea. It is involved in testing and substance screening, clinical pathology and histopathology work, and consulting and government affairs related to non-clinical trials, as well as new drug development. The company’s safety evaluation research field includes general toxicity test, carcinogenicity studies, local toxicity studies, reproductive and de...

• Industry: Medical Laboratories
• Founded: 2000
• Employees: 188
• Stock Exchange: KOSDAQ
• Ticker Symbol: 086040

Financial Performance

In 2024, Biotoxtech's revenue was 41.34 billion, an increase of 26.69% compared to the previous year's 32.63 billion. Losses were -6.43 billion, 31.8% more than in 2023.